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ABSTRACT: Consumption of cannabis by nontraditional methods has surged since
the advent of legalization in North America and worldwide. Inhaling cannabis extracts
using vaporizers and via dabbing has risen in popularity, while concerns over product
safety have not hindered their proliferation. The work herein is the first step toward
assessing the safety of vaporizing and dabbing concentrated cannabis extracts as a
function of gas-phase reaction products. The gas-phase thermal degradants of Δ9-
tetrahydrocannabinol (THC) have not been previously investigated. It was found that
users may be exposed to concerning degradants such as methacrolein, benzene, and
methyl vinyl ketone when using cartridge vaporizers and dabbing. It was shown that
THC alone and mixed with terpenes generated similar degradation products and, most notably, elevated levels of isoprene.
Importantly, it was shown that added terpenes led to higher levels of gas-phase products compared to THC alone. To estimate
cancer and noncancer risks associated with exposure to these and other degradants, quantitative risk assessment was applied to
experimentally determined values for dabbing and vaping and literature-sourced levels of hazardous components in cannabis
smoke. Overall, gas-phase aerosol products had significantly lower values in dabbing and vaporizing compared to cannabis
smoking, although these results should be interpreted in light of potential variations in degradant levels due to disparate usage
patterns and the dangers of the higher aerosol concentration of THC.
■ INTRODUCTION
Legalization and increasing social acceptance of cannabis in the
United States and worldwide has led to a proliferation of novel
cannabis administration methods. Advancement of cannabis
extract (CE) production and processing has placed these at the
forefront of novel cannabis inhalation methods, and sales of
CEs now make up more than 20% of the retail market share in
the Washington state.1 Despite their popularity, little work has
been done to assess the safety of these novel consumption
methods.
Cannabinoids, the constituents responsible for cannabis’
psychoactive and medicinal effects, are biosynthesized in
trichomes of female cannabis inflorescences.2−4 Figure 1
displays the pharmacologically active cannabinoids THC
(mp: <25 °C5) and cannabidiol (CBD, mp: 62−63 °C6),
which are biosynthesized as the acid cannabinoids Δ9-
tetrahydrocannabinolic acid (THCA, mp 75 ± 3 °C7) and
cannabidiolic acid (CBDA, mp 68 ± 3 °C8) that readily
decarboxylate upon heating.9 Nonpolar solvents (e.g.,
butane10−12 and supercritical CO2
13,14) are used to extract
acid cannabinoids in an oleoresin that includes terpenes, waxes,
fatty acids, steroids, lignins, etc.15 While butane hash oil
(BHO, an amber or gold solid10,16) contains primarily acid
cannabinoids,10,11 superfluid cannabis extract (SFE) may
contain acid or neutral cannabinoids depending on processing
methods. Vacuum distillation affords purified neutral cannabi-
noids allowing manufacturers to tailor cannabinoid and
terpene content in the final product commonly referred to as
a distillate.17 Distillates are often amended with terpenes at 5−
15% (m/m).18
Three consumption methods/devices for CEs have
predominated: dabbing, cartridge vaporizers (CVs), and top-
loading vaporizers (TLVs). Dabbing involves flash vaporizing a
small amount of CE, a dab, on a hot surface, a nail, which is
connected to a pipe or water pipe, an oil rig or rig.19 A user
quickly and immediately inhales aerosol generated when the
dab is placed onto the nail, which may require up to an entire
vital capacity for complete capture.11 BHO, distillate, and SFE
are amenable to dabbing, though BHO is most common.11,20
CVs are small electronic cigarette-like devices that use battery-
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powered resistive heating to aerosolize CEs. A button-activated
battery powers an atomizer located in a cartridge preloaded
with CE to generate aerosol a user inhales through a
mouthpiece; reliance on wicking necessitates extracts contain-
ing neutral THC with added terpenes to decrease viscosity.21
TLVs also use a battery to power a resistively heated coil but
differ in that users manually place the CE directly onto exposed
heating coils in the atomizer ad libitum.22 Any extract may be
used in TLV.22 Both TLV and CV are colloquially referred to
as vape pens, and no surveys to date distinguish between the
two, categorizing them together as cannabis e-cigarettes or
cannabis electronic vapor products (CEVPs). In all these CE
consumption methods, carrier liquids such as glycerol,
propylene glycol, and medium-chain triglycerides are not
typically included as they are considered to be undesirable.23
Vaporizing (or vaping) cannabis by any method has gained
popularity among recreational and medical users, particularly
young adults and teens,24 as a less detectable method of using
marijuana compared to smoking that is also perceived to be
healthier.25−27 Vaporizers for cannabis inflorescences28,29 have
existed long before popularization of CEs,30 and terminology
used to refer to these (e.g., vaporizers and vapes) has been
applied for TLV and CV, which has led to some confusion in
the literature. Several studies have investigated prevalence of
CEVPs specifically, though many others exist for inflorescence
vaporizers. The 2016 National Youth Tobacco Survey31
reported that nearly 1 in 11 respondents reported lifetime
use of a CEVP, and other state-level surveys report 3.4% usage
among middle-schoolers,32 5.4−11.4% for high-schoolers,32,33
and 10.7% for college students.34 Sparse data exists on
prevalence of dabbing, though it appears to be common
among regular cannabis users. Twenty percent of daily/nearly
daily cannabis users in the Washington state reported dabbing
in the past week,35 and 36.5% of respondents from a Reddit
survey of a similar cohort endorsed regular use of dabbing as
well.36 An internet survey of Twitter posts found that dabbing-
related posts are more prevalent in states with medical
marijuana laws,37 suggesting that dabbing may grow in
popularity as legalization of cannabis expands access to
alternative cannabis products.
The thermal behavior of cannabinoids has been studied in
the context of the conversion of CBD to THC or other
potentially psychoactive compounds in smoked marijuana,
smoked tobacco with CBD,38−41 and pyrolysis of CBD
alone.42,43 While searching for potentially psychoactive CBD
pyrolysis products, many olivetol derivatives with intact pentyl
chains (Figure 2, compds 1−5)44,45 and other products were
found to stem from rearrangement of CBD’s terpene moiety
(Figure 2, compds 6 and 7),46 indicating that this may be
particularly labile. Exhaustive in its efforts to identify potential
pharmacologically active products, work at the University of
Utrecht did not prioritize identifying volatile organic
compounds (VOCs). Harmful and potentially harmful
constituents (HPHCs) of cannabis smoke have been
previously studied,47,48 but no information is available
concerning pyrolysis or oxidation products of cannabinoids
relevant to dabbing or vaping conditions. Moreover, it is not
clear if the HPHCs arise from the cannabinoids, terpenes, or
any other plant constituents. A recent study described BHO
diluted in glycerol and propylene glycol added to a CV-type
device, which does not embody the manner in which cannabis
concentrates are vaporized.49 Evidence-based data is needed to
better understand toxicology and routes of administration of
these emerging products. We currently do not know, for
instance, the aerosol doses of cannabinoids, terpenes, and
potentially toxic degradation products being delivered to
vulnerable cohorts such as teens and pre-teens or to medical
marijuana patients with compromised immune systems.
Quantitative risk assessment (QRA) is an analytically driven
risk calculation that pools biological and chemical data to
approximate the probability of the incidence of a defined
outcome or symptom upon exposure to a given HPHC. QRA
has been previously performed for tobacco products,50,52 for
example, for comparison of “reduced exposure” cigarettes to
regular cigarettes.51 Cancer risk may be approximated using
the excess lifetime cancer risk (ELCR) and noncancer risks
using the hazard index (HI). ELCR, the incremental
probability of contracting cancer upon specified conditions of
exposure to a carcinogen,52 is derived from the inhalation unit
risk (IUR), an estimate of the increased risk (i.e., above
baseline) of developing cancer due to exposure to a 1 μg/m3
concentration of a given chemical.53 The reference exposure
level (REL) is an estimate of an air concentration that is not
likely to create an appreciable risk in humans after continuous
inhalation and is calculated in reference to a given symptom
that occurs after chronic exposure.53 Both the IUR and REL
may have uncertainties spanning an order of magnitude. A
given exposure concentration divided by the REL yields a
hazard quotient (HQ) wherein HQ > 1 indicates that the
threshold of toxic effects on the target system is surpassed.
ELCR and HQ values for individual chemicals are summed to
yield total ELCR (ELCRT) and HI, respectively, which may be
used to guide policy decisions regarding environmental
cleanup projects and consumer products.52
Previously, our lab had investigated thermal degradation
products of terpenes that are present in CEs when exposed to
dabbing conditions.19 We hypothesize that cannabinoids will
generate similar degradation products given their terpene
backbone. Given the restricted availability of marijuana
derivatives for research, it was possible only to synthetically
recreate the CE product distillate by mixing analytical-grade
THC with a terpene aromatherapy mix of cannabis cultivar
Fire OG in a ratio of 9:1 THC:terpenes. Herein, we report an
investigation of the chemical makeup of aerosol gas phases
(GPs) obtained by dabbing pure THC and this synthetic
distillate (SND) in addition to vaping SND in a CV device at
three power levels commonly used. Adsorption/thermal
desorption gas chromatography−mass spectrometry (ATD-
GCMS) is used to quantify target VOC analytes, and other
aerosol GP components are estimated using a nontarget
analysis approach. Identified components provide mechanistic
insight into the thermal degradation of cannabinoids.
Quantitative risk assessment (QRA) calculations are appliedFigure 2. Cannabidiol degradation products.
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to estimate cancer and noncancer risks from dabbing and CV
usage, and the results of which are compared to risks from
smoking cannabis using quantitated cannabis smoke compo-
nents from the literature.55−58 To the best of our knowledge,
this is the first time the safety of CEVP and dabbing has been
studied, and the first time quantitative risk assessment has been
used to evaluate the safety of cannabis smoking.
■ RESULTS
GP aerosol components generated from dabbing THC and
SND were quantified using internal standard (IS)-normalized
multipoint calibration of methacrolein, benzene, xylenes,
toluene, styrene, and ethylbenzene in duplicate samples, and
response factors (RFs) calculated from ISs were used to
estimate levels of these components seen from vaping SND in
a CV at three voltages (Table 1). Isoprene levels were
estimated using internal standard-calculated response factors
(IS-RFs) in all cases. A large diversity of other hydrocarbon
(HC) components with a majority of alkenes was observed in
all GCMS chromatograms acquired, though the spread differed
between SND dabbing (Table S1) and THC dabbing samples
(Table S2). Levels of the major-occurring VOCs, identified by
comparison of mass spectra against those in the National
Institute for Standards and Technology (NIST) mass
spectrometry database (match qualities of >70%), were
estimated by a previously published nontarget analysis method
(see Methods and Materials),58,59 and the results of which are
displayed in Tables S1 and S2. GP components from dabs of
11 ± 2.5 mg of either THC or SND were measured and scaled
up to 40 mg (reported average dab60), assuming equivalent
sidestream losses of the GP components across different dab
sizes. For CV vaping, GP components are presented from
single-puff measurements using standard puff topography for e-
cigarettes. Many oxygenated compounds identified in the THC
dabbing chromatograms (2,5-dimethylfuran, 2,3-dimethylacro-
lein, etc.) were not identifiable in SND dabbing and CV vaping
chromatograms. Analysis of selected ion chromatograms of
ions relevant to these oxygenated products in SND samples
indicates the presence of these THC-specific degradation
products, though they were not quantifiable by nontarget
analysis due to overlap from vastly more abundant alkenic
terpene degradation products. Sample chromatograms from
dabbing THC and SND are presented in the Supporting
Information (Figures S1 and S2). A sample chromatogram of
CV vaping was not displayed given its similarity to that of SND
dabbing.
To make the comparison between the risks associated with
CV vaping, dabbing, and smoking, the level of chronic
consumption of each was matched so each would deliver an
equivalent daily dose of THC. This was necessary given the
lack of information about specific consumption habits for CV
vaping and dabbing but is justified based on literature
precedence. Van Dam et al.61 reported a significant decrease
in daily grams of cannabis consumed in users that switched
from smoking to vaporizing flower cannabis, which has a THC
delivery efficiency higher than that of smoking,62 suggesting
that users adjust the quantity consumed to obtain the same
THC delivery based on personal preference. Analogous to the
pack-year for cigarette smoking, the joint-year has been used as
a measure of cannabis consumption widely used in
epidemiological studies of cannabis use63−65 and is defined
as smoking 1 joint/day over the course of a year. The joint-
year was chosen as the reference point to which approximate
THC deliveries for dabbing and CV vaping would be matched
by the consumption rate (CR; see Methods and Materials).
Assuming a THC content of 17.1%66 in cannabis and a THC
transfer efficiency of 43%62,67 during smoking, a standard 0.75
g joint68,69 would yield 55 mg of THC, two 40 mg dabs would
yield 55 mg of THC assuming a THC content of 90% and a
transfer efficiency of 76%,70 and 20 puffs from a vape pen (at
4.8 V) would yield 54 mg of THC assuming an 85% yield on 4
mg puffs of cannabis distillate containing 90% THC (m/m).
■ DISCUSSION
The identification of several carbonyls, aromatics, and isoprene
was in line with a previous report from our lab.19 Given that all
the terpenes tested in Meehan-Atrash et al.19 resulted in a
comparable array of volatile products, it was hypothesized that
isoprene is an intermediate in the degradation of these
compounds. Cannabinoids such as THC contain a terpene
backbone, and it is not surprising that similar volatile products
are generated from dabbing THC, SND, and terpenes alone.19
A diversity of degradation mechanisms may occur upon
thermal treatment of THC, but the significant levels of
isoprene seen when dabbing THC alone indicate that the
isoprene formed undergoes oxidation to release methacrolein
and methyl vinyl ketone, a mechanism for which has been
described in the context of atmospheric oxidation.71,72
Isoprene has been previously described as a neutral product
formed during fragmentation of THC in electron impact mass
spectrometry.73−75 The nearly fivefold increase in isoprene
released from THC amended with ∼10% terpenes compared
Table 1. Selected GP Components Identified in Dabbing and CV Vaping Using ATD-GCMSa
component, unit THC dab SND dab vape, 3.2 V vape, 4.0 V vape, 4.8 V
methacrolein, μg 2.7 ± 0.8 12 ± 0.82 5.6 × 10−3 3.2 × 10−2 1.9 × 10−1
benzene, ng 33 ± 14 360 ± 120 9.9 × 10−1 2.7 × 100 3.6 × 101
xylenes, μg 0.33 ± 0.20 0.85 ± 0.30 1.0 × 10−3 1.5 × 10−2 1.8 × 10−1
toluene, μg 0.44 ± 0.22 1.4 ± 0.42 7.0 × 10−4 1.0 × 10−2 1.6 × 10−1
styrene, ng 0.88 ± 0.72 27 ± 14 9.3 × 10−2 2.7 × 10−1 NDb
ethylbenzene, ng 1.5 ± 0.99 55 ± 30 3.7 × 10−2 2.5 × 10−1 2.7 × 100
isoprene, μg 9.6 ± 1.7 44 ± 3.5 3.0 × 10−2 8.3 × 10−1 6.0 × 100
other HCs,c μg 5.3 ± 0.7 21 ± 11 4.2 × 10−2 7.2 × 10−1 7.9 × 100
total VOCs,d μg 2.0 × 101 7.7 × 101 9.4 × 10−2 1.5 × 100 1.2 × 101
aFor THC and SND dabbing, these were quantified by IS calibration and average for duplicate samples and are presented for a single 40 mg dab ±
SEM. Isoprene levels in dabbing were estimated by IS-RF analysis. GP components for vaping at three voltages are from single-puff measurements
estimated using IS-RF analysis. bStyrene was not detected in CV vaping at 4.8 V due to overlap of alkenic terpene degradation products. cNontarget
HCs not otherwise specified on this table. dTotal of all VOCs quantified.
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to THC alone (Table 1) suggests that terpenes release
isoprene more readily than THC. Indeed, all identified VOCs
form in higher amounts per milligram of product consumed
when dabbing SND than from THC alone. Other minor
components in CEs (hydrocarbons, fatty acids, flavonoids,
phenols, etc.15) may add to or alter GP degradants of other
extract formulations.
The work presented herein represents a preliminary
investigation into the GP aerosol components a cannabis
consumer may be exposed to when vaping distillate in a CV or
via dabbing. Several identified components are International
Agency for Research on Cancer-classified carcinogens, and
exposure to these may place a burden on the health of people
that use dabbing or vaping to consume cannabis. In an attempt
to interpret results in the most relevant way possible to health
professionals and consumers alike, components for which
toxicological metrics had been previously calculated were
applied to a QRA calculation. Despite the rise in alternative
cannabis administration methods, cannabis smoking remains to
be the more prevalent mode of cannabis consumption to
date,30,76,77 warranting a systematic comparison between
methods of inhalation. Previously quantified components of
cannabis smoke were aggregated from the literature54−57 and
correspondingly applied to the same QRA analysis in a first
attempt to compare the relative safety of smoking cannabis to
two existing methods of vaporizing distillate.
Results indicate that vaping or dabbing distillates has lower
HI and ELCR than those of cannabis smoking by several
orders of magnitude (Table 2). These findings are not
definitive and must be interpreted with caution as they are
only a first step toward determining the overall safety of these
cannabis inhalation methods. Only GP components were
measured in this work and were applied to QRA calculations,
which may underestimate risks due to exclusion of potentially
toxic particulate phase components. Previous literature
indicates that aldehydes/small organics contribute the largest
percentage of the total cancer risk among constituents of
cigarette smoke,50 which appears to hold true for cannabis
smoke as well (Table S4). Furthermore, HI and ELCR are only
measures of chronic effects and do not indicate relative safety
in the context of acute effects, particularly in light of the recent
rash of vaping related illnesses, the cause of which has not been
fully identified.
Though widely used by regulatory bodies to make evidence-
based decisions on environmental risks to human health,
quantitative risk assessment has several unavoidable sources of
uncertainty, which is currently magnified due to the lack of
standardization in the study of cannabis consumption as
compared to tobacco. Machine smoking attempts to imitate
realistic use but is only an approximation.52 In this study, a puff
profile set by the Cooperation Center for Scientific Research
Relative to Tobacco (CORESTA) for e-cigarettes was chosen
given the functional similarity of these devices to e-cigarettes;
however, puffing topography for CEVPs has not been studied,
which represents another source of systematic error of
unknown magnitude in the work herein. When calculating
ELCR and HI, it is assumed that 100% of each component is
absorbed and that the total risk is the sum of the risk from each
individual component, which may over- or underestimate the
total risk. For cigarette smoking, it has been noted that ELCR
values underestimate risks when these are compared to
epidemiological data.50 However, the cancer risk for cannabis
smoking calculated herein, which is comparable to that
calculated for cigarette smoking,50 is in stark contrast to the
negligible association between cannabis smoking and cancer.78
In regard to noncancer effects, the major contributor to the
elevated HI for cannabis smoking, acrolein, could potentially
be responsible for the association between cannabis smoking
and respiratory symptoms.79,80 Given the uncertainty asso-
ciated with QRA, dabbing HI may exceed unity under altered
conditions such as increased nail temperature, which has been
shown to linearly increase degradant formation,19 or increased
terpene content. Ninety-one percent of the HI from dabbing
stems from methacrolein; the REL of which stems from
chronic respiratory tract effects (Table S3) and has been
specifically implicated as the cause of lung injury due to
dabbing BHO in a medical case report.81 The elevated levels of
conjugated dienes (Table S1 and S2) warrant mention as these
have been implicated as prohaptens.82 The complete absence
of detectable acrolein in dabbing and vaping GP warrants
mention as it may imply that this cannabis smoke component
stems from plant components other than cannabinoids and
terpenes.
Despite the reduction in the toxicant yield for CE vaporizers
compared to smoking and the corresponding low HI and
ELCR values, the elevated concentration of THC in the total
particulate matter (TPM) may have untold physicochemical83
and pharmacological effects84 on the respiratory system. For
example, cannabis smoke with ∼1% THC content was shown
to compromise the surface properties of a lung surfactant
replacement product83 due to intercalation of the hydrophobic
THC molecule. The effect of higher concentrations of THC
and high-molecular weight terpenes in the aerosol particulate
phase and any partitioning85 of GP dienes and other VOCs
into the lung surfactant layer warrants further investigation.
■ CONCLUSIONS
ATD-GCMS identified and quantified gaseous degradants
using calibrated standards for target analytes, and a nontarget
analysis approach was used for other components identified in
the chromatograms. Given the similarity of compounds
identified in these experiments to those found when dabbing
terpenes alone,19 GP degradants seen when dabbing THC
alone were also assessed. The similarity in degradation
products seen, particularly the elevated levels of isoprene
seen across the board, suggests an analogous degradation
mechanism for cannabinoids and terpenes. Higher levels of
terpenes appear to promote increased production of VOCs.
Toxicants measured were applied to a QRA calculation to
estimate cancer and noncancer risks for dabbing and vaping
with a CV. In order to compare these results with cannabis
smoking, cannabis smoke component levels were taken from
Table 2. Hazard Index and Excess Lifetime Cancer Risk for
Smoking, Dabbing, and Vaping at Three Voltagesa
consumption type HI ELCR
smoking (inflorescence) 2 × 102 4 × 10−4
dabbing (distillate) 2 × 10−1 2 × 10−7
vaping 4.8 V (distillate) 4 × 10−2 2 × 10−7
4.0 V (distillate) 6 × 10−3 2 × 10−8
3.2 V (distillate) 8 × 10−4 2 × 10−9
aHI and ELCR for each consumption method calculated using eqs
2−5. HI and ELCR assume consumption of one 0.75 g joint, two 40
mg dabs, and 20 puffs from a CV vape for each voltage.
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the literature and applied to a QRA calculation. This represents
the first time any degradation products have been identified
from vaporizing CE components and is a first step toward
understanding the degradation mechanism of THC via this
route of administration. Additionally, the work herein is the
first application of QRA to cannabis smoking to the best of our
knowledge.
The development of novel cannabis inhalation products has
outpaced both basic and applied biomedical research. This has
hindered the ability of regulatory agencies from properly
informing the public about the safety of these products and
their routes of administration. Future work in our labs will
focus on identifying other volatile organics that have not yet
been detected in the GP, such as formaldehyde and carbon
monoxide, and components of the particulate phase that are
potentially toxicologically relevant. Further work must assess
the biological impact these aerosols have on the respiratory
system.
■ METHODS AND MATERIALS
Materials. Analytical-grade THC was obtained from
Cayman Chemical (Ann Arbor, MI). A terpene aromatherapy
mix recreating the scent of cannabis cultivar Fire OG was
obtained from Blue River (Oakland, CA) and is referred to
hereafter as simply “terpenes.” To make SND, terpenes were
introduced into THC at ∼10%. Verispec 200 ppm Aromatic
Hydrocarbons Mixture 16 Components in Methanol EPA
503.1 was obtained from Ricca Chemical Company (Arlington,
TX). An isoprene SPEXOrganics Certified Reference Material
analytical standard (1000 μg/mL) was obtained from SPEX
CertiPrep (Metuchen, NJ).
Sample Collection for Dabbing. An air flow was
generated with a Welch 8907 rotary-vane vacuum pump
(Mt. Prospect, IL), regulated with a Cole-Parmer PTFE
multiturn needle valve (Vernon Hills, IL), and measured with
an Aalborg GFM17 mass flow meter (Orangeburg, NY). A
flow rate of 400−450 mL/min was chosen to minimize
breakthrough of volatile components from the adsorption/
thermal desorption (ATD) cartridge while maximizing vapor
collection from the e-nail. The ATD cartridge was situated
between two Pyrex T-Bore, three-way, glass key stopcocks
(Corning, NY). Vapor was generated on a Jibtronix Corp.
Errlectric Concentration Station (Gurnee, IL) e-nail heated to
∼370 °C. The temperature used was chosen based on realistic
use and was assessed thermographically using a FLIR System
T450sc (Wilsonville, OR) as in Meehan-Atrash et al.19 A by-
pass line circumventing the ATD cartridge facilitated sample
collection by maintaining a constant backpressure between
experiments. All connections were made using 3/8 in. outer
diameter ACF0017-F Tygon S3 E-3603 (Saint-Gobain,
Malvern, PA). All experiments were performed by collecting
GPs generated from a single dab of 11 ± 2.5 mg of either THC
or SND. Figure 3 (top) depicts the experimental setup used for
collection of the aerosol GP generated from dabbing.
Sample Collection for CV Vaping. A CH Technologies
cigarette smoking machine (CSM, Westwood, NJ) ran a puff
program modified from CORESTA with 55 mL puff volume
over a 3 s puff duration with an additional 1 s after the
conclusion of each puff to clear the lines of aerosol (vaporizer
button was only depressed during the 3 s puffs). Aerosol was
generated using a CCell TH2 oil cartridge (Sneaky Pete
vaporizers) loaded with SND and connected to an Innokin
iTaste VV V3.0 variable voltage battery. The atomizer was
rated at 1.4−1.5 Ω according to the digital display provided by
the battery. All connections were made using 3/8 in. outer
diameter ACF0017-F Tygon S3 E-3603. Vaping experiments
were conducted using single puffs at three voltages chosen
based on realistic use: 3.2, 4.0, and 4.8 V, which consumed 1−
4 mg of SND per puff. Figure 3 (bottom) depicts the
experimental setup used for collection of the aerosol GP
generated from vaping.
Adsorption/Thermal Desorption Gas Chromatogra-
phy−Mass Spectrometry. GP samples were collected
through a 47 mm Cambridge filter pad (CFP, GE Healthcare)
onto an ATD cartridge, which contains 100 mg of 35/60 mesh
Tenax TA and 200 mg of 60/80 mesh Carbograph 1 TD
(Camsco Inc., Houston, TX). ATD sample cartridges were
thermally desorbed with a TurboMatrix 650 ATD unit
(PerkinElmer, Waltham, MA). Twenty nanograms of fluo-
robenzene, 18.6 ng of toluene-d8, 21.7 ng of 4-bromofluor-
obenzene, and 20.3 ng of 1,2-dichlorobenzene-d4 were added
automatically to all cartridges as ISs prior to desorption. The
Figure 3. Experimental setups used for dabbing (top) and CV (bottom) vapor collection by ATD-GCMS. Components depicted are the (a) e-nail,
(b) CFP holder, (c) three-way stopcock, (d) ATD cartridge, (e) mass flow meter, (f) flow control valve, (g) vacuum source, (h) by-pass line, (i)
CV, and (j) CSM.
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ATD unit thermally desorbed the ATD cartridges for 10 min at
285 °C with a He desorption flow of 40 mL/min, a split flow
of 10 mL/min, and the desorption stream was trapped at −10
°C on an intermediate “Tenax trap.” Thermal desorption of
this intermediate trap occurred at 295 °C and 35 psi constant
pressure of He on a split flow of 12 mL/min for 4 min.
Through a 1 m long and 0.25 mm i.d. deactivated fused silica
transfer line (235 °C), the unsplit portion of the stream was
passed on to a 60 m length, 0.25 mm i.d., and 1.4 μm film
thickness Agilent (Santa Clara, CA) DB-VRX capillary GC
column mounted in an Agilent 7890A GC. The GC was
interfaced to an Agilent 5975C MS in impact ionization at 70
eV in the positive ion mode. GC oven temperature was held at
45 °C for 10 min, programming to 190 °C at 12 °C/min, held
at 190 °C for 2 min, then programming to 240 °C at 6 °C/
min, held at 240 °C for 5 min, and then programmed down to
210 °C at 10 °C/min. The MS scan range was 34 to 400 amu,
and the electron multiplier voltage was 1725 V.
Quantification of Components from CV Vaping and
Dabbing. An ATD-GCMS IS-normalized multipoint calibra-
tion was generated for quantifying select analytes for dabbing
experiments. A standardized solution of methacrolein and the
components in the Verispec 200 ppm aromatic hydrocarbons
mixture were made at concentrations of 6.25−200 ng/μL in
serial dilution. An additional solution of 250 ng/μL isoprene
was made using the SPEXOrganics Certified Reference
Material. Two microliters of each chosen standard solution
was spiked through a 0.25” Swagelok tee onto the inlet end of
each ATD cartridge with a flow of 50 mL/min of N2 gas. After
spiking, the N2 flow was left on for ∼7 min to purge the
methanol solvent. Six ATD cartridges were amended with 0,
3.125, 12.5, 25, 50, and 100 ng of each component from
standard solutions containing methacrolein and the Verispec
200 ppm aromatic hydrocarbons mixture components. An
additional cartridge was amended with 500 ng of isoprene
only.
IS-RF factors for the 17 analytes used in the multipoint
calibration and isoprene were calculated and used to estimate
the concentration of these in the ATD-GCMS samples from
three cannabis vaping experiments. Analytes in addition to
those used in the multipoint calibration were tentatively
identified by comparison of their mass spectra against those in
the NIST mass spectrometry database. Quantification of some
major-occurring alkenes, carbonyls, and aromatics was
performed using a nontarget analysis approach based on one
described in Fitch et al.58 and Allgood et al.59 Nontarget
analytes were chosen based on abundance, integrated in the
total ion chromatogram (TIC), and their molecular formula
from the tentative match (all match qualities of >70%) was
used to calculate their total ionization cross section (Q) using
the regression equation from Fitch et al.58 The Q of an IS was
used to determine the levels of the nontarget analyte using eq 1














where A is the integrated TIC area and N is the number of
moles of the analyte (a) and IS.
Cannabis Smoke Component Literature Review.
Literature reports containing pertinent data were searched in
multiple scientific databases including but not limited to
SciFinder and Web of Science. Values for cannabis smoke
HPHCs from all reports containing quantitative data were
used. Smoke component identities and their measured values
were pulled from the four references deemed suitable for this
analysis.54−57 Other relevant information such as puff top-
ography, cannabis consumed per experiment, and joint sizes
were also noted. HPHC levels were presented as mass HPHC
per joint,56 parts per million concentrations,54 mass HPHC per
gram cannabis consumed,55 and mass HPHC per milligram
TPM collected.57 All component levels identified were
converted to microgram HPHC per gram of cannabis using
the reported joint size. This was subsequently converted to
microgram HPHC per 0.75 g joint, which was chosen as the
standard joint mass. HPHCs were assigned CAS numbers, and
levels of identical HPHCs were binned and averaged together.
Quantitative Risk Assessment. Toxicological metrics for
cancer and chronic noncancer effects for HPCs identified in
the GP of the aerosol from vaping, dabbing, and smoking were
searched in relevant databases. The IUR was used for cancer
risk assessment, and RELs were used for noncancer effects.
IUR values were accessed from the Integrated Risk
Information System (IRIS) online database provided by the
United State Environmental Protection Agency86 and
supplemented with values from the California Office of
Environmental Health and Hazard Assessment (OEHHA)
online chemical database.87 REL values were taken as an
inhalation reference concentration (RfC) from IRIS86 or as a
reference value (ReV) from the Texas Commission on
Environmental Quality (TCEQ).88 Given the high levels of
isoprene observed from vaping and dabbing, the IUR value for
isoprene was found in the literature89 given its absence in IRIS,
OEHHA, and TCEQ databases.
Quantitative Risk Assessment for Cancer Effects.
ELCR as defined in Marano et al.52 for each HPHC i for
which an IUR value exists was calculated using eq 2, adapted
from Marano et al.:52
=
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where CYi is the yield for a given gaseous HPHC, CU is the
consumption unit, CR is the consumption rate, ED is the
exposure duration, EF is the exposure frequency, IR is the
inhalation rate, and ATC is the averaging time for cancer
effects. CU is a consumption method-dependent unit (vaping:
CU = puffs, dabbing: CU = dabs, and smoking: CU = joints).
CYi is the experimentally determined yield of a given HPHC
given in micrograms per CU. As per United States Food and
Drug Administration recommendations,52 ED is taken as the
difference of the default lifetime expectancy of 70 years52 and
the age of initiation, which for cannabis consumption is taken
as 16 years based on literature precedence.90−96 EF assumes
daily consumption at 365.25 days/year. IR is taken as the
human reference value of 20 m3/day.52 ATC prorates the
cumulative intake of the component over a lifetime of 70 years
expressed in days (25567.5 days).52 Taking the assumption of
dose additivity, the ELCRi for each component may be
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Quantitative Risk Assessment for Noncancer Effects.
HQ, as previously defined,52 for a given component i (HQi)
for which an REL exists was calculated using eq 4, adapted
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where ATNC is the averaging time for noncancer effects, which
averages component intake over the ED, for a value of 19723.5
days assuming an ED of 54 years. HI, as previously defined, is
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release from heated ‘street’ cannabis leaf and its potential toxic effects
on cannabis users. Addiction 2008, 103, 1671−1677.
(55) Gieringer, D.; Laurent, J. S.; Goodrich, S. Cannabis Vaporizer
Combines Efficient Delivery of THC with Effective Suppression of
Pyrolytic Compounds. J. Cannabis Ther. 2004, 4, 7−27.
(56) Moir, D.; Rickert, W. S.; Levasseur, G.; Larose, Y.; Maertens,
R.; White, P.; Desjardins, S. A comparison of mainstream and
sidestream marijuana and tobacco cigarette smoke produced under
two machine smoking conditions. Chem. Res. Toxicol. 2008, 21, 494−
502.
(57) Maertens, R. M.; White, P. A.; Rickert, W.; Levasseur, G.;
Douglas, G. R.; Bellier, P. V.; McNamee, J. P.; Thuppal, V.; Walker,
M.; Desjardins, S. The genotoxicity of mainstream and sidestream
marijuana and tobacco smoke condensates. Chem. Res. Toxicol. 2009,
22, 1406−1414.
(58) Fitch, W. L.; Sauter, A. D. Calculation of Relative Electron
Impact Total Ionization Cross Sections for Organic Molecules. Anal.
Chem. 1983, 55, 832−835.
(59) Allgood, C.; Orlando, R.; Munson, B. Correlations of relative
sensitivities in gas chromatography electron ionization mass
spectrometry with molecular parameters. J. Am. Soc. Mass Spectrom.
1990, 1, 397−404.
(60) Raber, J. C.; Elzinga, S.; Kaplan, C. Understanding dabs:
contamination concerns of cannabis concentrates and cannabinoid
transfer during the act of dabbing. J. Toxicol. Sci. 2015, 40, 797−803.
(61) Van Dam, N. T.; Earleywine, M. Pulmonary function in
cannabis users: Support for a clinical trial of the vaporizer. Int. J. Drug
Policy 2010, 21, 511−513.
(62) Pomahacova, B.; Van der Kooy, F.; Verpoorte, R. Cannabis
smoke condensate III: the cannabinoid content of vaporised Cannabis
sativa. Inhalation Toxicol. 2009, 21, 1108−1112.
(63) Hashibe, M.; Morgenstern, H.; Cui, Y.; Tashkin, D. P.; Zhang,
Z.-F.; Cozen, W.; Mack, T. M.; Greenland, S. Marijuana use and the
risk of lung and upper aerodigestive tract cancers: Results of a
population-based case-control study. Cancer Epidemiol. Biomarkers
Prev. 2006, 15, 1829−1834.
(64) Hancox, R. J.; Poulton, R.; Ely, M.; Welch, D.; Taylor, D. R.;
McLachlan, C. R.; Greene, J. M.; Moffitt, T. E.; Caspi, A.; Sears, M. R.
Effects of cannabis on lung function: a population-based cohort study.
Eur. Respir. J. 2009, 35, 42−47.
(65) Aldington, S.; Williams, M.; Nowitz, M.; Weatherall, M.;
Pritchard, A.; McNaughton, A.; Robinson, G.; Beasley, R. Effects of
cannabis on pulmonary structure, function and symptoms. Thorax
2007, 62, 1058−1063.
(66) Chandra, S.; Radwan, M. M.; Majumdar, C. G.; Church, J. C.;
Freeman, T. P.; Elsohly, M. A. New trends in cannabis potency in
USA and Europe during the last decade (2008−2017). Eur. Arch.
Psychiatry Clin. Neurosci. 2019, 269, 5−15.
(67) Van der Kooy, F.; Pomahacova, B.; Verpoorte, R. Cannabis
smoke condensate I: the effect of different preparation methods on
tetrahydrocannabinol levels. Inhalation Toxicol. 2008, 20, 801−804.
(68) Zhang, L. R.; Morgenstern, H.; Greenland, S.; Chang, S.-C.;
Lazarus, P.; Teare, M. D.; Woll, P. J.; Orlow, I.; Cox, B.; Brhane, Y.;
Liu, G.; Hung, R. J. Cannabis smoking and lung cancer risk: Pooled
analysis in the International Lung Cancer Consortium. Int. J. Cancer
2015, 136, 894−903.
(69) WHO. Cannabis a health perspective and research agenda; World
Health Organization, 1997.
(70) Had̈ener, M.; Vieten, S.; Weinmann, W.; Mahler, H. A
preliminary investigation of lung availability of cannabinoids by
smoking marijuana or dabbing BHO and decarboxylation rate of
THC- and CBD-acids. Forensic Sci. Int. 2019, 295, 207−212.
(71) Atkinson, R.; Arey, J. Atmospheric degradation of volatile
organic compounds. Chem. Rev. 2003, 103, 4605−4638.
(72) Atkinson, R. Gas-phase Tropospheric Chemistry of Organic
Compounds: A Review. Atmos. Environ. 1990, 24, 1−41.
(73) Harvey, D. J. Mass spectrometry of the cannabinoids and their
metabolites. Mass Spectrom. Rev. 1987, 6, 135−229.
(74) Holler, J. M.; Smith, M. L.; Paul, S. N.; Past, M. R.; Paul, B. D.
Isomerization of delta-9-THC to delta-8-THC when tested as
trifluoroacetyl-, pentafluoropropionyl-, or heptafluorobutyryl- deriva-
tives. J. Mass Spectrom. 2008, 43, 674−679.
(75) Terlouw, J. K.; Heerma, W.; Burgers, P. C.; Dijkstra, G.; Boon,
A.; Kramer, H. F.; Salemink, C. A. The use of metastable ion
characteristics for the determination of ion structures of some
isomeric cannabinoids. Tetrahedron 1974, 30, 4243−4248.
(76) Lintzeris, N.; Driels, J.; Elias, N.; Arnold, J. C.; McGregor, I. S.;
Allsop, D. J. Medicinal cannabis in Australia, 2016: the Cannabis as
Medicine Survey (CAMS-16). Med. J. Australia 2018, 209, 211−216.
(77) Cranford, J. A.; Bohnert, K. M.; Perron, B. E.; Bourque, C.;
Ilgen, N. Prevalence and correlates of “Vaping” as a route of cannabis
administration in medical cannabis patients. Drug Alcohol Depend.
2016, 169, 41−47.
(78) Huang, Y.-H. J.; Zhang, Z.-F.; Tashkin, D. P.; Feng, B.; Straif,
K.; Hashibe, M. An epidemiologic review of marijuana and cancer: an
update. Cancer Epidemiol. Biomarkers Prev. 2015, 24, 15−31.
(79) Ghasemiesfe, M.; Ravi, D.; Vali, M.; Korenstein, D.; Arjomandi,
M.; Frank, J.; Austin, P. C.; Keyhani, S. Marijuana use, respiratory
symptoms, and pulmonary function. Ann. Intern. Med. 2018, 169,
106−116.
(80) Meehan-Atrash, J.; Korzun, T.; Ziegler, A. Cannabis inhalation
and voice disorders. JAMA Otolaryngol, Head Neck Surg. 2019,
DOI: 10.1001/jamaoto.2019.1986.
(81) Anderson, R. P.; Zechar, K. Lung injury from inhaling butane
hash oil mimics pneumonia. Respir. Med. Case Rep. 2019, 26, 171−
173.
(82) Nilsson, A. M.; Bergström, M. A.; Luthman, K.; Nilsson, J. L.
G.; Karlberg, A. T. A conjugated diene identified as a prohapten:
Contact allergenic activity and chemical reactivity of proposed
epoxide metabolites. Chem. Res. Toxicol. 2005, 18, 308−316.
(83) Davies, M. J.; Birkett, J. W.; Court, O.; Mottram, A.; Zoroaster,
F. The impact of cannabis smoke on the performance of pulmonary
surfactant under physiologically relevant conditions. Surf. Interface
Anal. 2018, 50, 188−197.
(84) Turcotte, C.; Blanchet, M. R.; Laviolette, M.; Flamand, N.
Impact of cannabis, cannabinoids, and endocannabinoids in the lungs.
Front. Pharmacol. 2016, 7, 317.
(85) Pankow, J. F. A consideration of the role of gas/particle
partitioning in the deposition of nicotine and other tobacco smoke
compounds in the respiratory tract. Chem. Res. Toxicol. 2001, 14,
1465−1481.
(86) USEPA. Integrated Risk Information System (Online Database of
Toxicity Values). United States Environmental Protection Agency:
2018, https://www.epa.gov/iris (accessed June 6, 2019)
(87) CALEPA. Online OEHHA Chemical Database. California Office
of Environmental Health and Hazard Assessment, California Environ-
mental Protection Agency: 2019, https://oehha.ca.gov/chemicals
(accessed June 6, 2019).
(88) TCEQ. Development Support Documents. Texas Commission on
Environmenta Quality. https://www.tceq.texas.gov/toxicology/dsd
(accessed June 6, 2019).
ACS Omega Article
DOI: 10.1021/acsomega.9b02301
ACS Omega 2019, 4, 16111−16120
16119
(89) Haney, J. T., Jr.; Phillips, T.; Sielken, R. L., Jr.; Valdez-Flores, C.
Development of an inhalation unit risk factor for isoprene. Regul.
Toxicol. Pharmacol. 2015, 73, 712−725.
(90) Clark, T. T.; Doyle, O.; Clincy, A. Age of First Cigarette,
Alcohol, and Marijuana Use Among U.S. Biracial/Ethnic Youth: A
Population-Based Study. Addict. Behav. 2013, 38, 2450−2454.
(91) Hayatbakhsh, R.; Williams, G. M.; Bor, W.; Najman, J. M. Early
childhood predictors of age of initiation to use of cannabis: A birth
prospective study. Drug Alcohol Rev. 2013, 32, 232−240.
(92) Henchoz, Y.; N’Goran, A. A.; Baggio, S.; Deline, S.; Studer, J.;
Gmel, G. Associations of age at cannabis first use and later substance
abuse with mental health and depression in young men. J. Subst. Use
2015, 21, 85−91.
(93) Melchior, M.; Bolze, C.; Fombonne, E.; Surkan, P. J.; Pryor, L.;
Jauffret-Roustide, M. Early cannabis initiation and educational
attainment: is the association causal? Data from the French
TEMPO study. Int. J. Epidemiol. 2017, 46, 1641−1650.
(94) Sokol, N. A.; Okechukwu, C. A.; Chen, J. T.; Subramanian, S.
V.; Rees, V. W. Maternal Cannabis Use During a Child’s Lifetime
Associated With Earlier Initiation. Am. J. Prev. Med. 2018, 55, 592−
602.
(95) O’Connell, T. J.; Bou-Matar, C. B. Long term marijuana users
seeking medical cannabis in California (2001−2007): demographics,
social characteristics, patterns of cannabis and other drug use of 4117
applicants. Harm Reduct. J. 2007, 4, 16.
(96) Borodovsky, J. T.; Crosier, B. S.; Lee, D. C.; Sargent, J. D.;
Budney, A. J. Smoking, vaping, eating: Is legalization impacting the
way people use cannabis? Int. J. Drug Policy 2016, 36, 141−147.
ACS Omega Article
DOI: 10.1021/acsomega.9b02301
ACS Omega 2019, 4, 16111−16120
16120
